Stocks Health care ADXN
NASDAQ · Health careAddex Therapeutics Ltd. (ADXN)
Addex Therapeutics Ltd. reported revenue of CHF 404.1K in fiscal 2024, down 74.9% from a year earlier. Net income was CHF 7.1M, a net margin of 1,746.0%. In fiscal 2024 capital spending exceeded operating cash flow by CHF 5.4M. At December 31, 2024 it held CHF 3.3M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on May 15, 2026.
Key facts about Addex Therapeutics Ltd.
- Net worth
- Addex Therapeutics Ltd. has a market value (market cap) of $3.7M at the latest share price, and shareholders' equity of CHF 9.7M on its balance sheet at December 31, 2024. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2024 operations used CHF 5.4M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on May 15, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Addex Therapeutics Ltd. does
Addex Therapeutics Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ADXN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | CHF 404.1K | CHF 7.1M | CHF 0.07 | -CHF 5.4M |
| 2023 | CHF 1.6M | -CHF 10.6M | -CHF 0.14 | -CHF 8M |
| 2022 | CHF 1.4M | -CHF 20.8M | -CHF 0.46 | -CHF 16.4M |
| 2021 | CHF 2.9M | -CHF 15.4M | -CHF 0.45 | -CHF 14.7M |
| 2020 | CHF 3.6M | -CHF 12.9M | -CHF 0.48 | -CHF 12.2M |
| 2019 | CHF 2.8M | -CHF 14.8M | -CHF 0.56 | -CHF 9.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Addex Therapeutics Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 2, 2026
- September 28, 2026
- September 25, 2026
- September 4, 2026Activist stake changed SCHEDULE 13D/A
- August 27, 2026Activist stake changed SCHEDULE 13D/A
- August 26, 2026
- July 8, 2026
- June 30, 2026
- June 25, 2026
- June 5, 2026
Insider trades
What the people running Addex Therapeutics Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 14 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | Dyer Timothy MarkCHIEF EXECUTIVE OFFICER, Director | Other change | 16,413,787 | - |
| September 2, 2026 | Dyer Timothy MarkCHIEF EXECUTIVE OFFICER, Director | Received as pay | 16,413,787 | - |
| September 2, 2026 | Hill Raymond GeorgeDirector | Other change | 1,365,532 | - |
| September 2, 2026 | Hill Raymond GeorgeDirector | Received as pay | 1,365,532 | - |
| September 2, 2026 | Lawton Vincent MichaelDirector | Other change | 2,507,487 | - |
| September 2, 2026 | Lawton Vincent MichaelDirector | Received as pay | 2,507,487 | - |
| September 2, 2026 | Manke IsaacDirector | Other change | 219,561 | - |
| September 2, 2026 | Manke IsaacDirector | Received as pay | 219,561 | - |
Who owns ADXN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| I.R.S. Identification No(s). of above person(s) (entities only) Timothy Mark Dyer13D, may seek influence | 14.16% | November 29, 2023 |
| Timothy Mark Dyer13D, may seek influence | 9.01% | September 4, 2026 |
| Growth Equity Opportunities Fund IV, LLC13D, may seek influence with 7 related filers | 5.1% | August 5, 2024 |
Largest institutional holders
Insiders
7 insiders reported holding 22,254,361 shares in total, about $63.6M at the last price.
| Holder | Shares |
|---|---|
| Dyer Timothy MarkCHIEF EXECUTIVE OFFICER, Director | 16,848,979 |
| Lawton Vincent MichaelDirector | 2,507,987 |
| Hill Raymond GeorgeDirector | 1,365,532 |
| Mills RogerCHIEF MEDICAL OFFICER, Director | 785,976 |
| Kalinichev MikhailHEAD OF TRANSLATIONAL SCIENCE | 306,765 |
| Nunn Jason RaleighDirector | 219,561 |
| Manke IsaacDirector | 219,561 |
Questions about ADXN
What does Addex Therapeutics Ltd. do?
Addex Therapeutics Ltd. is a company in the Health care sector, listed on NASDAQ as ADXN. Its shares trade on NASDAQ under the ticker ADXN.
What is Addex Therapeutics Ltd.'s net worth?
Addex Therapeutics Ltd. has a market value (market cap) of $3.7M at the latest share price, and shareholders' equity of CHF 9.7M on its balance sheet at December 31, 2024. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Addex Therapeutics Ltd. profitable?
Yes. In fiscal 2024 it reported net income of CHF 7.1M on revenue of CHF 404.1K, a net margin of 1,746.0%.
How much revenue does Addex Therapeutics Ltd. make?
In fiscal 2024 Addex Therapeutics Ltd. reported revenue of CHF 404.1K. That is 74.9% less than a year earlier.
When did Addex Therapeutics Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on May 15, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from October 2, 2026.
Similar companies
Compare ADXN with
Follow ADXN
Get an email when Addex Therapeutics Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Addex Therapeutics Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.